{"gene":"TRIM66","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2019,"finding":"The PHD-Bromo tandem domain of TRIM66 recognizes unmodified H3R2-H3K4 and acetylated H3K56 (H3K56ac). TRIM66 recruits Sirt6 to deacetylate H3K56ac, negatively regulating H3K56ac levels and facilitating initiation of DNA damage repair (DDR) in embryonic stem cells. Aberrant deletion of Trim66 results in severe DNA damage and genomic instability in ESCs.","method":"Structural/biochemical domain binding assays, co-immunoprecipitation, loss-of-function genetics in ESCs, histone modification analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (domain binding, Co-IP, KO with defined phenotype, histone modification profiling), single lab but rigorous","pmids":["31537782"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of TRIM66's PHD finger reveals recognition of H3K4-K9me3. TRIM66 recruits the co-repressor DAX1 to the Dux promoter, and this repressive effect on Dux is dependent on DAX1. TRIM66 and DAX1 together act as negative regulators of the 2-cell-like (2CLC) state in murine ESCs. Mutational evidence confirmed that TRIM66's PHD finger is essential for repression of Dux.","method":"Crystal structure determination, chimeric assays, co-repressor recruitment assays, mutagenesis, promoter reporter assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional mutagenesis validation and chimeric embryo assays, single lab but multiple orthogonal methods","pmids":["35659877"],"is_preprint":false},{"year":2025,"finding":"TRIM66 interacts with HP1γ through the PxVxL motif. TRIM66-HP1γ co-phase separation (liquid-liquid phase separation, LLPS) occurs both in vitro and in vivo. The liquid granules of TRIM66-HP1γ co-localize with H3K9me3 chromatin sites, linking this complex to DNA damage response. TRIM66 remodels chromatin into compressed facultative heterochromatin through the TRIM66-HP1γ-H3K9me3 axis.","method":"Biophysical assays (LLPS in vitro), live-cell imaging, chromatin co-localization, interaction domain mapping","journal":"Biophysics reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution of phase separation plus in vivo validation, single lab, multiple orthogonal methods","pmids":["40070663"],"is_preprint":false},{"year":2024,"finding":"Biophysical assays showed TRIM66 PHD-Bromodomain binds to the H3 N-terminus only when lysine 4 is unmethylated. TRIM66 is primarily expressed in post-meiotic male germ cells (spermatids). Trim66-null round spermatids up-regulated genes involved in histone acetylation and H3K4 methylation. Trim66-null males sired overweight pups (paternal effect phenotype), but sperm H3K4me3 patterns showed only minor, statistically non-significant alterations.","method":"Biophysical binding assays, loss-of-function genetics (null mice), H3K4me3 ChIP profiling, transcriptomic profiling of spermatids, in vivo breeding phenotype","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biophysical assay plus in vivo genetics with defined phenotype, single lab, multiple orthogonal methods","pmids":["38719749"],"is_preprint":false},{"year":2019,"finding":"Knockdown of TRIM66 reduced activation of JAK2/STAT3 signaling pathway in colorectal cancer cells, inhibiting proliferation, migration, invasion, and EMT (increased E-cadherin; decreased N-cadherin and vimentin). Treatment with JAK2/STAT3 inhibitor AG490 enhanced the inhibitory effects of TRIM66 knockdown.","method":"shRNA knockdown, western blot for pathway components, functional cell assays (proliferation, migration, invasion), pharmacological inhibitor epistasis","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — KD with defined cellular phenotype and pharmacological epistasis, single lab","pmids":["31472144"],"is_preprint":false},{"year":2019,"finding":"TRIM66 regulates GSK-3β phosphorylation and β-catenin expression in hepatocellular carcinoma cells, promoting Wnt/β-catenin signaling activation. Inhibition of GSK-3β by specific inhibitor partially reversed TRIM66 inhibition-mediated antitumor effect, while knockdown of β-catenin blocked the oncogenic effect of TRIM66 overexpression.","method":"siRNA knockdown and overexpression, western blot, pharmacological GSK-3β inhibitor, rescue experiments, xenograft tumor model","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — gain/loss-of-function with pathway epistasis using inhibitor and β-catenin KD, single lab","pmids":["30710548"],"is_preprint":false},{"year":2020,"finding":"TRIM66 positively regulates STAT2 and IL-2 expression in prostate cancer cells. Overexpression of STAT2 or IL-2 almost completely abolished the inhibitory effects on proliferation, migration, and invasion elicited by TRIM66 deficiency, placing TRIM66 upstream of a STAT2-IL-2 signaling axis.","method":"shRNA knockdown, rescue overexpression experiments, cell functional assays","journal":"FEBS open bio","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single approach (KD + rescue), no direct binding demonstrated","pmids":["31981447"],"is_preprint":false},{"year":2022,"finding":"TRIM66 physically interacts with MMP9 in non-small cell lung cancer cells, as validated by co-immunoprecipitation. TRIM66 regulates MMP9 expression, and MMP9 overexpression activates the TGF-β/SMAD pathway. Rescue experiments with si-MMP9 or TGF-β/SMAD inhibitor SB431542 partially reversed phenotypes induced by TRIM66 overexpression.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression, TGF-β/SMAD pathway analysis, rescue experiments, xenograft tumor model","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP for direct interaction plus pathway epistasis with pharmacological inhibitor, single lab","pmids":["35301175"],"is_preprint":false},{"year":2021,"finding":"TRIM66 promotes glucose uptake and metabolism in glioma by upregulating cMyc and GLUT3. Depletion of cMyc by siRNA abolished the effect of TRIM66 on GLUT3. ChIP assay showed that cMyc binds to the promoter regions of GLUT3 in glioblastoma cells, placing TRIM66 upstream of a cMyc/GLUT3 signaling axis.","method":"siRNA knockdown and overexpression, glucose uptake/consumption assays, western blot, ChIP assay, xenograft model","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — genetic epistasis (cMyc KD rescue) plus ChIP for downstream mechanism, single lab","pmids":["34234562"],"is_preprint":false},{"year":2021,"finding":"c-Myc directly binds to the TRIM66 promoter and regulates its expression in androgen-independent prostate cancer cells, as demonstrated by luciferase reporter assay and chromatin immunoprecipitation. TRIM66 interacts with HP1γ to form a TRIM66/HP1γ/AR signaling axis that promotes androgen-independent prostate cancer progression.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), western blot, cell proliferation/apoptosis assays","journal":"Complementary medicine research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ChIP and luciferase reporter for direct promoter binding, single lab, two orthogonal methods","pmids":["34077947"],"is_preprint":false},{"year":2023,"finding":"TRIM66 forms a transcription complex with BLIMP1 (B lymphocyte-induced maturation protein 1) in decidual tissue, co-regulating COX2 expression. Co-immunoprecipitation confirmed direct interaction between TRIM66 and BLIMP1. In vivo mouse experiments with si-Blimp1 or overexpression plasmids showed that both BLIMP1 and TRIM66 affect the initiation of parturition.","method":"Co-immunoprecipitation, ChIP-seq (for BLIMP1 binding to PTGS2/COX2), adenoviral overexpression/knockdown in mice","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP for direct interaction, ChIP-seq for promoter binding, in vivo validation, single lab","pmids":["37515773"],"is_preprint":false},{"year":2025,"finding":"TRIM66 functions as an epigenetic repressor of olfactory receptor (OR) gene expression in olfactory sensory neurons. Upon Trim66 deletion, multiple OR genes are retained at low levels in most single mature olfactory sensory neurons, leading to decreased expression of the vast majority of OR genes. Mechanistically, TRIM66 binds to, assembles, and represses OR enhancers, thereby silencing extra OR genes and ensuring monogenic OR expression. Trim66 deletion causes severe defects in olfactory information processing and innate olfactory behaviors.","method":"Conditional knockout mouse, single-cell RNA-seq, enhancer binding/assembly assays, olfactory behavior assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo KO with defined cellular and behavioral phenotype, enhancer binding assays, single-cell transcriptomics, single lab but multiple orthogonal methods","pmids":["41387398"],"is_preprint":false},{"year":2021,"finding":"TRIM66 knockdown in MDA-MB-468 triple negative breast cancer cells inhibited expression of EGFR, P-JAK2, P-STAT3, JAK2, and STAT3, placing TRIM66 upstream of EGFR/JAK2/STAT3 signaling in TNBC.","method":"siRNA knockdown, western blot, CCK8, clonogenicity, TUNEL assay","journal":"Polish journal of pathology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single KD approach, no direct binding or mechanistic link established","pmids":["34706523"],"is_preprint":false}],"current_model":"TRIM66 is a chromatin 'reader' protein whose PHD-Bromo tandem domain recognizes unmodified H3K4 (and H3R2) together with H3K56ac or H3K9me3 context; it recruits Sirt6 to deacetylate H3K56ac and facilitates DNA damage repair in ESCs, interacts with HP1γ via a PxVxL motif to drive liquid-liquid phase separation and facultative heterochromatin formation, recruits the co-repressor DAX1 to silence the Dux locus (suppressing the 2-cell-like totipotent state), represses olfactory receptor enhancers to enforce monogenic OR gene expression, and in cancer contexts activates JAK2/STAT3, Wnt/β-catenin, and TGF-β/SMAD pathways partly through physical interactions with MMP9 and a transcriptional complex with BLIMP1 that co-regulates COX2."},"narrative":{"mechanistic_narrative":"TRIM66 is a chromatin reader that uses its PHD-Bromo tandem domain to interpret a defined histone-tail code and convert it into transcriptional repression and genome-protective programs [PMID:31537782, PMID:35659877, PMID:31472144]. Its PHD finger engages the H3 N-terminus only when lysine 4 is unmethylated and reads adjacent marks, recognizing unmodified H3R2-H3K4 alongside H3K56ac as well as an H3K4-H3K9me3 configuration [PMID:31537782, PMID:35659877, PMID:31472144]. Through this reader activity TRIM66 recruits the deacetylase Sirt6 to remove H3K56ac, restraining H3K56ac levels to license DNA damage repair, such that loss of Trim66 produces severe DNA damage and genomic instability in embryonic stem cells [PMID:31537782]. It additionally recruits the co-repressor DAX1 to the Dux promoter to suppress the 2-cell-like totipotent state, a repression dependent on an intact PHD finger [PMID:35659877]. TRIM66 interacts with HP1γ via a PxVxL motif and undergoes co-phase separation that compacts chromatin into facultative heterochromatin along a TRIM66-HP1γ-H3K9me3 axis [PMID:40070663]. These repressive activities operate in defined cell lineages: in post-meiotic spermatids TRIM66 loss derepresses histone-modifying genes and produces a paternal-effect phenotype [PMID:31472144], and in olfactory sensory neurons TRIM66 binds, assembles, and represses olfactory receptor enhancers to silence extra OR genes and enforce monogenic OR expression required for normal olfactory behavior [PMID:41387398]. In cancer contexts TRIM66 acts as an oncogenic driver, activating JAK2/STAT3 signaling [PMID:31472144], promoting Wnt/β-catenin signaling through GSK-3β and β-catenin [PMID:30710548], physically interacting with MMP9 to engage the TGF-β/SMAD pathway [PMID:35301175], and forming a transcriptional complex with BLIMP1 that co-regulates COX2 in decidual tissue [PMID:37515773].","teleology":[{"year":2019,"claim":"Established TRIM66 as a histone reader that translates a specific tail code into active genome protection, answering how it influences chromatin state mechanistically.","evidence":"Domain binding assays, Co-IP, and Trim66 loss-of-function in ESCs with histone modification profiling","pmids":["31537782"],"confidence":"High","gaps":["Whether TRIM66 directly deacetylates or only recruits Sirt6 enzymatic activity at specific loci","Genome-wide targeting rules of the PHD-Bromo module not defined"]},{"year":2019,"claim":"Linked TRIM66 to oncogenic signaling by showing it is required to activate JAK2/STAT3 and drive EMT in colorectal cancer.","evidence":"shRNA knockdown with pharmacological JAK2/STAT3 inhibitor epistasis and functional cell assays","pmids":["31472144"],"confidence":"Medium","gaps":["No direct physical interaction with JAK2/STAT3 components shown","Connection between chromatin-reader activity and pathway activation unresolved"]},{"year":2019,"claim":"Extended the oncogenic role to Wnt/β-catenin, placing TRIM66 upstream of GSK-3β and β-catenin in hepatocellular carcinoma.","evidence":"Knockdown/overexpression with GSK-3β inhibitor and β-catenin knockdown rescue plus xenograft","pmids":["30710548"],"confidence":"Medium","gaps":["Direct molecular target connecting TRIM66 to GSK-3β phosphorylation not identified"]},{"year":2020,"claim":"Implicated TRIM66 in a STAT2-IL-2 axis in prostate cancer, broadening its signaling repertoire.","evidence":"shRNA knockdown with STAT2/IL-2 overexpression rescue and cell functional assays","pmids":["31981447"],"confidence":"Low","gaps":["Single approach without direct binding demonstration","No mechanistic link to chromatin function"]},{"year":2021,"claim":"Defined a feed-forward circuit in which c-Myc directly drives TRIM66 transcription while TRIM66 partners HP1γ and AR in prostate cancer.","evidence":"Luciferase reporter and ChIP for c-Myc binding to TRIM66 promoter plus interaction and proliferation assays","pmids":["34077947"],"confidence":"Medium","gaps":["Stoichiometry and direct contacts within the TRIM66/HP1γ/AR axis not resolved"]},{"year":2021,"claim":"Connected TRIM66 to tumor metabolism by showing it acts upstream of a cMyc/GLUT3 axis controlling glucose uptake in glioma.","evidence":"siRNA/overexpression with glucose uptake assays, cMyc rescue, and ChIP for cMyc-GLUT3 binding plus xenograft","pmids":["34234562"],"confidence":"Medium","gaps":["Mechanism by which TRIM66 elevates cMyc unknown","Direct chromatin targets of TRIM66 in glioma not mapped"]},{"year":2021,"claim":"Reinforced the EGFR/JAK2/STAT3 connection in triple negative breast cancer.","evidence":"siRNA knockdown with western blot and functional/apoptosis assays","pmids":["34706523"],"confidence":"Low","gaps":["Single knockdown approach with no direct binding or mechanistic link","Not independently validated by orthogonal methods"]},{"year":2022,"claim":"Resolved the structural basis for combinatorial mark reading and identified DAX1-dependent silencing of Dux as the route to suppressing the 2C-like totipotent state.","evidence":"Crystal structure of the PHD finger, mutagenesis, co-repressor recruitment and promoter reporter assays, chimeric embryo assays","pmids":["35659877"],"confidence":"High","gaps":["How DAX1 recruitment is integrated with Sirt6 and HP1γ activities not defined","In vivo developmental consequences of Dux derepression incomplete"]},{"year":2022,"claim":"Provided direct physical evidence linking TRIM66 to MMP9 and the TGF-β/SMAD pathway in lung cancer.","evidence":"Co-IP for TRIM66-MMP9 interaction, knockdown/overexpression with si-MMP9 and SB431542 rescue plus xenograft","pmids":["35301175"],"confidence":"Medium","gaps":["Whether interaction is direct or complex-mediated not distinguished","Domain mediating MMP9 binding unmapped"]},{"year":2023,"claim":"Identified a TRIM66-BLIMP1 transcriptional complex co-regulating COX2 in reproductive tissue, demonstrating a defined co-factor partnership.","evidence":"Co-IP, BLIMP1 ChIP-seq on PTGS2/COX2, and adenoviral in vivo manipulation in mice","pmids":["37515773"],"confidence":"Medium","gaps":["Direct TRIM66 occupancy at COX2 versus indirect via BLIMP1 not separated","Histone-reader contribution to this complex untested"]},{"year":2024,"claim":"Confirmed the unmethylated-H3K4 reading rule biophysically and placed TRIM66 as a repressor of histone-modifying genes in male germ cells with a paternal-effect phenotype.","evidence":"Biophysical binding assays, null mice, H3K4me3 ChIP, spermatid transcriptomics, in vivo breeding","pmids":["38719749"],"confidence":"Medium","gaps":["Molecular basis of the paternal metabolic phenotype unresolved","Sperm H3K4me3 changes only minor and non-significant"]},{"year":2025,"claim":"Demonstrated HP1γ-driven phase separation as the biophysical mechanism by which TRIM66 compacts facultative heterochromatin.","evidence":"In vitro LLPS reconstitution, live-cell imaging, chromatin co-localization, interaction domain mapping","pmids":["40070663"],"confidence":"Medium","gaps":["Functional necessity of LLPS for in vivo gene silencing not directly tested","Relationship between phase separation and Sirt6/DAX1 recruitment unknown"]},{"year":2025,"claim":"Established TRIM66 as an enhancer-level repressor enforcing monogenic olfactory receptor expression, defining a physiological singular-gene-choice role.","evidence":"Conditional knockout mice, single-cell RNA-seq, enhancer binding/assembly assays, olfactory behavior tests","pmids":["41387398"],"confidence":"High","gaps":["How TRIM66 selects which OR enhancers to repress not defined","Link between enhancer assembly and the histone-reader/HP1γ modules untested in neurons"]},{"year":null,"claim":"How TRIM66's chromatin-reader and heterochromatin-forming activities mechanistically connect to its pro-oncogenic activation of cytoplasmic signaling pathways remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking nuclear repressor function to JAK2/STAT3, Wnt, and TGF-β activation","Genome-wide direct binding map across tissues lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,10,11]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,11]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,1,2,11]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,7]}],"complexes":[],"partners":["CBX3","NR0B1","SIRT6","MMP9","PRDM1","AR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15016","full_name":"Tripartite motif-containing protein 66","aliases":[],"length_aa":1351,"mass_kda":149.5,"function":"May function as transcription repressor; The repressive effects are mediated, at least in part, by recruitment of deacetylase activity. May play a role as negative regulator of postmeiotic genes acting through CBX3 complex formation and centromere association (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O15016/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRIM66","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":77,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRIM66","total_profiled":1310},"omim":[{"mim_id":"612000","title":"TRIPARTITE MOTIF-CONTAINING PROTEIN 66; TRIM66","url":"https://www.omim.org/entry/612000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":13.0}],"url":"https://www.proteinatlas.org/search/TRIM66"},"hgnc":{"alias_symbol":["KIAA0298","TIF1D"],"prev_symbol":["C11orf29"]},"alphafold":{"accession":"O15016","domains":[{"cath_id":"-","chopping":"2-35","consensus_level":"medium","plddt":79.8438,"start":2,"end":35},{"cath_id":"-","chopping":"882-909","consensus_level":"medium","plddt":68.2625,"start":882,"end":909},{"cath_id":"1.20.920.10","chopping":"987-1032_1040-1156","consensus_level":"high","plddt":92.2412,"start":987,"end":1156}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15016","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15016-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15016-F1-predicted_aligned_error_v6.png","plddt_mean":54.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRIM66","jax_strain_url":"https://www.jax.org/strain/search?query=TRIM66"},"sequence":{"accession":"O15016","fasta_url":"https://rest.uniprot.org/uniprotkb/O15016.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15016/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15016"}},"corpus_meta":[{"pmid":"30481109","id":"PMC_30481109","title":"LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30481109","citation_count":48,"is_preprint":false},{"pmid":"31537782","id":"PMC_31537782","title":"TRIM66 reads unmodified H3R2K4 and H3K56ac to respond to DNA damage in embryonic stem cells.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31537782","citation_count":35,"is_preprint":false},{"pmid":"31472144","id":"PMC_31472144","title":"Knockdown of TRIM66 inhibits cell proliferation, migration and invasion in colorectal cancer through JAK2/STAT3 pathway.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31472144","citation_count":35,"is_preprint":false},{"pmid":"30710548","id":"PMC_30710548","title":"TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3β-dependent Wnt/β-catenin signaling.","date":"2019","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30710548","citation_count":26,"is_preprint":false},{"pmid":"35659877","id":"PMC_35659877","title":"A TRIM66/DAX1/Dux axis suppresses the totipotent 2-cell-like state in murine embryonic stem cells.","date":"2022","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/35659877","citation_count":23,"is_preprint":false},{"pmid":"31981447","id":"PMC_31981447","title":"TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/31981447","citation_count":20,"is_preprint":false},{"pmid":"34613933","id":"PMC_34613933","title":"Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34613933","citation_count":20,"is_preprint":false},{"pmid":"29929749","id":"PMC_29929749","title":"Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer.","date":"2018","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/29929749","citation_count":17,"is_preprint":false},{"pmid":"30915743","id":"PMC_30915743","title":"TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30915743","citation_count":15,"is_preprint":false},{"pmid":"35301175","id":"PMC_35301175","title":"TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway.","date":"2022","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/35301175","citation_count":11,"is_preprint":false},{"pmid":"34234562","id":"PMC_34234562","title":"TRIM66 Overexpression Promotes Glioma Progression and Regulates Glucose Uptake Through cMyc/GLUT3 Signaling.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/34234562","citation_count":10,"is_preprint":false},{"pmid":"35912155","id":"PMC_35912155","title":"TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9.","date":"2022","source":"Computational and mathematical methods in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35912155","citation_count":8,"is_preprint":false},{"pmid":"31434545","id":"PMC_31434545","title":"miR-451a Inhibits the Growth and Invasion of Osteosarcoma via Targeting TRIM66.","date":"2019","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31434545","citation_count":7,"is_preprint":false},{"pmid":"35211152","id":"PMC_35211152","title":"Effects of miR-103a-3p Targeted Regulation of TRIM66 Axis on Docetaxel Resistance and Glycolysis in Prostate Cancer Cells.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35211152","citation_count":7,"is_preprint":false},{"pmid":"38084627","id":"PMC_38084627","title":"Circ-SATB2 (hsa_circ_0008928) and miR-150-5p are regulators of TRIM66 in the regulation of NSCLC cell growth and metastasis of NSCLC cells via the ceRNA pathway.","date":"2023","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38084627","citation_count":6,"is_preprint":false},{"pmid":"34706523","id":"PMC_34706523","title":"Knockdown of TRIM66 in MDA-MB-468 triple negative breast cancer cell line suppresses proliferation and promotes apoptosis through EGFR signaling.","date":"2021","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/34706523","citation_count":6,"is_preprint":false},{"pmid":"34573402","id":"PMC_34573402","title":"Association of the SNP rs112369934 near TRIM66 Gene with POAG Endophenotypes in African Americans.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34573402","citation_count":6,"is_preprint":false},{"pmid":"34077947","id":"PMC_34077947","title":"Qi Ling Inhibits Progression of Androgen-Independent Prostate Cancer via Negative Regulation of TRIM66/HP1γ/AR Axis.","date":"2021","source":"Complementary medicine research","url":"https://pubmed.ncbi.nlm.nih.gov/34077947","citation_count":4,"is_preprint":false},{"pmid":"41387398","id":"PMC_41387398","title":"An epigenetic repressor TRIM66 dictates monogenic olfactory receptor expression, neural activity, and olfactory behavior.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41387398","citation_count":2,"is_preprint":false},{"pmid":"40070663","id":"PMC_40070663","title":"TRIM66-HP1γ remodels the chromatin through phase separation.","date":"2025","source":"Biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/40070663","citation_count":2,"is_preprint":false},{"pmid":"35733786","id":"PMC_35733786","title":"Circ_0051079 silencing inhibits the malignant phenotypes of osteosarcoma cells by the TRIM66/Wnt/β-catenin pathway in a miR-625-5p-dependent manner.","date":"2022","source":"Journal of bone oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35733786","citation_count":2,"is_preprint":false},{"pmid":"38719749","id":"PMC_38719749","title":"Trim66's paternal deficiency causes intrauterine overgrowth.","date":"2024","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/38719749","citation_count":1,"is_preprint":false},{"pmid":"37515773","id":"PMC_37515773","title":"Mechanism of BLIMP1/TRIM66/COX2 in human decidua participates in parturition†.","date":"2023","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/37515773","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13667,"output_tokens":3475,"usd":0.046563,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11159,"output_tokens":4169,"usd":0.08001,"stage2_stop_reason":"end_turn"},"total_usd":0.126573,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"The PHD-Bromo tandem domain of TRIM66 recognizes unmodified H3R2-H3K4 and acetylated H3K56 (H3K56ac). TRIM66 recruits Sirt6 to deacetylate H3K56ac, negatively regulating H3K56ac levels and facilitating initiation of DNA damage repair (DDR) in embryonic stem cells. Aberrant deletion of Trim66 results in severe DNA damage and genomic instability in ESCs.\",\n      \"method\": \"Structural/biochemical domain binding assays, co-immunoprecipitation, loss-of-function genetics in ESCs, histone modification analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (domain binding, Co-IP, KO with defined phenotype, histone modification profiling), single lab but rigorous\",\n      \"pmids\": [\"31537782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of TRIM66's PHD finger reveals recognition of H3K4-K9me3. TRIM66 recruits the co-repressor DAX1 to the Dux promoter, and this repressive effect on Dux is dependent on DAX1. TRIM66 and DAX1 together act as negative regulators of the 2-cell-like (2CLC) state in murine ESCs. Mutational evidence confirmed that TRIM66's PHD finger is essential for repression of Dux.\",\n      \"method\": \"Crystal structure determination, chimeric assays, co-repressor recruitment assays, mutagenesis, promoter reporter assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional mutagenesis validation and chimeric embryo assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"35659877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIM66 interacts with HP1γ through the PxVxL motif. TRIM66-HP1γ co-phase separation (liquid-liquid phase separation, LLPS) occurs both in vitro and in vivo. The liquid granules of TRIM66-HP1γ co-localize with H3K9me3 chromatin sites, linking this complex to DNA damage response. TRIM66 remodels chromatin into compressed facultative heterochromatin through the TRIM66-HP1γ-H3K9me3 axis.\",\n      \"method\": \"Biophysical assays (LLPS in vitro), live-cell imaging, chromatin co-localization, interaction domain mapping\",\n      \"journal\": \"Biophysics reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution of phase separation plus in vivo validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"40070663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Biophysical assays showed TRIM66 PHD-Bromodomain binds to the H3 N-terminus only when lysine 4 is unmethylated. TRIM66 is primarily expressed in post-meiotic male germ cells (spermatids). Trim66-null round spermatids up-regulated genes involved in histone acetylation and H3K4 methylation. Trim66-null males sired overweight pups (paternal effect phenotype), but sperm H3K4me3 patterns showed only minor, statistically non-significant alterations.\",\n      \"method\": \"Biophysical binding assays, loss-of-function genetics (null mice), H3K4me3 ChIP profiling, transcriptomic profiling of spermatids, in vivo breeding phenotype\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biophysical assay plus in vivo genetics with defined phenotype, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38719749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockdown of TRIM66 reduced activation of JAK2/STAT3 signaling pathway in colorectal cancer cells, inhibiting proliferation, migration, invasion, and EMT (increased E-cadherin; decreased N-cadherin and vimentin). Treatment with JAK2/STAT3 inhibitor AG490 enhanced the inhibitory effects of TRIM66 knockdown.\",\n      \"method\": \"shRNA knockdown, western blot for pathway components, functional cell assays (proliferation, migration, invasion), pharmacological inhibitor epistasis\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — KD with defined cellular phenotype and pharmacological epistasis, single lab\",\n      \"pmids\": [\"31472144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRIM66 regulates GSK-3β phosphorylation and β-catenin expression in hepatocellular carcinoma cells, promoting Wnt/β-catenin signaling activation. Inhibition of GSK-3β by specific inhibitor partially reversed TRIM66 inhibition-mediated antitumor effect, while knockdown of β-catenin blocked the oncogenic effect of TRIM66 overexpression.\",\n      \"method\": \"siRNA knockdown and overexpression, western blot, pharmacological GSK-3β inhibitor, rescue experiments, xenograft tumor model\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — gain/loss-of-function with pathway epistasis using inhibitor and β-catenin KD, single lab\",\n      \"pmids\": [\"30710548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIM66 positively regulates STAT2 and IL-2 expression in prostate cancer cells. Overexpression of STAT2 or IL-2 almost completely abolished the inhibitory effects on proliferation, migration, and invasion elicited by TRIM66 deficiency, placing TRIM66 upstream of a STAT2-IL-2 signaling axis.\",\n      \"method\": \"shRNA knockdown, rescue overexpression experiments, cell functional assays\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single approach (KD + rescue), no direct binding demonstrated\",\n      \"pmids\": [\"31981447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRIM66 physically interacts with MMP9 in non-small cell lung cancer cells, as validated by co-immunoprecipitation. TRIM66 regulates MMP9 expression, and MMP9 overexpression activates the TGF-β/SMAD pathway. Rescue experiments with si-MMP9 or TGF-β/SMAD inhibitor SB431542 partially reversed phenotypes induced by TRIM66 overexpression.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, TGF-β/SMAD pathway analysis, rescue experiments, xenograft tumor model\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP for direct interaction plus pathway epistasis with pharmacological inhibitor, single lab\",\n      \"pmids\": [\"35301175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM66 promotes glucose uptake and metabolism in glioma by upregulating cMyc and GLUT3. Depletion of cMyc by siRNA abolished the effect of TRIM66 on GLUT3. ChIP assay showed that cMyc binds to the promoter regions of GLUT3 in glioblastoma cells, placing TRIM66 upstream of a cMyc/GLUT3 signaling axis.\",\n      \"method\": \"siRNA knockdown and overexpression, glucose uptake/consumption assays, western blot, ChIP assay, xenograft model\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — genetic epistasis (cMyc KD rescue) plus ChIP for downstream mechanism, single lab\",\n      \"pmids\": [\"34234562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"c-Myc directly binds to the TRIM66 promoter and regulates its expression in androgen-independent prostate cancer cells, as demonstrated by luciferase reporter assay and chromatin immunoprecipitation. TRIM66 interacts with HP1γ to form a TRIM66/HP1γ/AR signaling axis that promotes androgen-independent prostate cancer progression.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), western blot, cell proliferation/apoptosis assays\",\n      \"journal\": \"Complementary medicine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ChIP and luciferase reporter for direct promoter binding, single lab, two orthogonal methods\",\n      \"pmids\": [\"34077947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM66 forms a transcription complex with BLIMP1 (B lymphocyte-induced maturation protein 1) in decidual tissue, co-regulating COX2 expression. Co-immunoprecipitation confirmed direct interaction between TRIM66 and BLIMP1. In vivo mouse experiments with si-Blimp1 or overexpression plasmids showed that both BLIMP1 and TRIM66 affect the initiation of parturition.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq (for BLIMP1 binding to PTGS2/COX2), adenoviral overexpression/knockdown in mice\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP for direct interaction, ChIP-seq for promoter binding, in vivo validation, single lab\",\n      \"pmids\": [\"37515773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRIM66 functions as an epigenetic repressor of olfactory receptor (OR) gene expression in olfactory sensory neurons. Upon Trim66 deletion, multiple OR genes are retained at low levels in most single mature olfactory sensory neurons, leading to decreased expression of the vast majority of OR genes. Mechanistically, TRIM66 binds to, assembles, and represses OR enhancers, thereby silencing extra OR genes and ensuring monogenic OR expression. Trim66 deletion causes severe defects in olfactory information processing and innate olfactory behaviors.\",\n      \"method\": \"Conditional knockout mouse, single-cell RNA-seq, enhancer binding/assembly assays, olfactory behavior assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO with defined cellular and behavioral phenotype, enhancer binding assays, single-cell transcriptomics, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"41387398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM66 knockdown in MDA-MB-468 triple negative breast cancer cells inhibited expression of EGFR, P-JAK2, P-STAT3, JAK2, and STAT3, placing TRIM66 upstream of EGFR/JAK2/STAT3 signaling in TNBC.\",\n      \"method\": \"siRNA knockdown, western blot, CCK8, clonogenicity, TUNEL assay\",\n      \"journal\": \"Polish journal of pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single KD approach, no direct binding or mechanistic link established\",\n      \"pmids\": [\"34706523\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRIM66 is a chromatin 'reader' protein whose PHD-Bromo tandem domain recognizes unmodified H3K4 (and H3R2) together with H3K56ac or H3K9me3 context; it recruits Sirt6 to deacetylate H3K56ac and facilitates DNA damage repair in ESCs, interacts with HP1γ via a PxVxL motif to drive liquid-liquid phase separation and facultative heterochromatin formation, recruits the co-repressor DAX1 to silence the Dux locus (suppressing the 2-cell-like totipotent state), represses olfactory receptor enhancers to enforce monogenic OR gene expression, and in cancer contexts activates JAK2/STAT3, Wnt/β-catenin, and TGF-β/SMAD pathways partly through physical interactions with MMP9 and a transcriptional complex with BLIMP1 that co-regulates COX2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRIM66 is a chromatin reader that uses its PHD-Bromo tandem domain to interpret a defined histone-tail code and convert it into transcriptional repression and genome-protective programs [#0, #1, #4]. Its PHD finger engages the H3 N-terminus only when lysine 4 is unmethylated and reads adjacent marks, recognizing unmodified H3R2-H3K4 alongside H3K56ac as well as an H3K4-H3K9me3 configuration [#0, #1, #4]. Through this reader activity TRIM66 recruits the deacetylase Sirt6 to remove H3K56ac, restraining H3K56ac levels to license DNA damage repair, such that loss of Trim66 produces severe DNA damage and genomic instability in embryonic stem cells [#0]. It additionally recruits the co-repressor DAX1 to the Dux promoter to suppress the 2-cell-like totipotent state, a repression dependent on an intact PHD finger [#1]. TRIM66 interacts with HP1\\u03b3 via a PxVxL motif and undergoes co-phase separation that compacts chromatin into facultative heterochromatin along a TRIM66-HP1\\u03b3-H3K9me3 axis [#2]. These repressive activities operate in defined cell lineages: in post-meiotic spermatids TRIM66 loss derepresses histone-modifying genes and produces a paternal-effect phenotype [#4], and in olfactory sensory neurons TRIM66 binds, assembles, and represses olfactory receptor enhancers to silence extra OR genes and enforce monogenic OR expression required for normal olfactory behavior [#11]. In cancer contexts TRIM66 acts as an oncogenic driver, activating JAK2/STAT3 signaling [#4], promoting Wnt/\\u03b2-catenin signaling through GSK-3\\u03b2 and \\u03b2-catenin [#5], physically interacting with MMP9 to engage the TGF-\\u03b2/SMAD pathway [#7], and forming a transcriptional complex with BLIMP1 that co-regulates COX2 in decidual tissue [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2019,\n      \"claim\": \"Established TRIM66 as a histone reader that translates a specific tail code into active genome protection, answering how it influences chromatin state mechanistically.\",\n      \"evidence\": \"Domain binding assays, Co-IP, and Trim66 loss-of-function in ESCs with histone modification profiling\",\n      \"pmids\": [\"31537782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRIM66 directly deacetylates or only recruits Sirt6 enzymatic activity at specific loci\", \"Genome-wide targeting rules of the PHD-Bromo module not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked TRIM66 to oncogenic signaling by showing it is required to activate JAK2/STAT3 and drive EMT in colorectal cancer.\",\n      \"evidence\": \"shRNA knockdown with pharmacological JAK2/STAT3 inhibitor epistasis and functional cell assays\",\n      \"pmids\": [\"31472144\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct physical interaction with JAK2/STAT3 components shown\", \"Connection between chromatin-reader activity and pathway activation unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the oncogenic role to Wnt/\\u03b2-catenin, placing TRIM66 upstream of GSK-3\\u03b2 and \\u03b2-catenin in hepatocellular carcinoma.\",\n      \"evidence\": \"Knockdown/overexpression with GSK-3\\u03b2 inhibitor and \\u03b2-catenin knockdown rescue plus xenograft\",\n      \"pmids\": [\"30710548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target connecting TRIM66 to GSK-3\\u03b2 phosphorylation not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated TRIM66 in a STAT2-IL-2 axis in prostate cancer, broadening its signaling repertoire.\",\n      \"evidence\": \"shRNA knockdown with STAT2/IL-2 overexpression rescue and cell functional assays\",\n      \"pmids\": [\"31981447\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single approach without direct binding demonstration\", \"No mechanistic link to chromatin function\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a feed-forward circuit in which c-Myc directly drives TRIM66 transcription while TRIM66 partners HP1\\u03b3 and AR in prostate cancer.\",\n      \"evidence\": \"Luciferase reporter and ChIP for c-Myc binding to TRIM66 promoter plus interaction and proliferation assays\",\n      \"pmids\": [\"34077947\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and direct contacts within the TRIM66/HP1\\u03b3/AR axis not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected TRIM66 to tumor metabolism by showing it acts upstream of a cMyc/GLUT3 axis controlling glucose uptake in glioma.\",\n      \"evidence\": \"siRNA/overexpression with glucose uptake assays, cMyc rescue, and ChIP for cMyc-GLUT3 binding plus xenograft\",\n      \"pmids\": [\"34234562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which TRIM66 elevates cMyc unknown\", \"Direct chromatin targets of TRIM66 in glioma not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reinforced the EGFR/JAK2/STAT3 connection in triple negative breast cancer.\",\n      \"evidence\": \"siRNA knockdown with western blot and functional/apoptosis assays\",\n      \"pmids\": [\"34706523\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single knockdown approach with no direct binding or mechanistic link\", \"Not independently validated by orthogonal methods\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved the structural basis for combinatorial mark reading and identified DAX1-dependent silencing of Dux as the route to suppressing the 2C-like totipotent state.\",\n      \"evidence\": \"Crystal structure of the PHD finger, mutagenesis, co-repressor recruitment and promoter reporter assays, chimeric embryo assays\",\n      \"pmids\": [\"35659877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DAX1 recruitment is integrated with Sirt6 and HP1\\u03b3 activities not defined\", \"In vivo developmental consequences of Dux derepression incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided direct physical evidence linking TRIM66 to MMP9 and the TGF-\\u03b2/SMAD pathway in lung cancer.\",\n      \"evidence\": \"Co-IP for TRIM66-MMP9 interaction, knockdown/overexpression with si-MMP9 and SB431542 rescue plus xenograft\",\n      \"pmids\": [\"35301175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether interaction is direct or complex-mediated not distinguished\", \"Domain mediating MMP9 binding unmapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a TRIM66-BLIMP1 transcriptional complex co-regulating COX2 in reproductive tissue, demonstrating a defined co-factor partnership.\",\n      \"evidence\": \"Co-IP, BLIMP1 ChIP-seq on PTGS2/COX2, and adenoviral in vivo manipulation in mice\",\n      \"pmids\": [\"37515773\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TRIM66 occupancy at COX2 versus indirect via BLIMP1 not separated\", \"Histone-reader contribution to this complex untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Confirmed the unmethylated-H3K4 reading rule biophysically and placed TRIM66 as a repressor of histone-modifying genes in male germ cells with a paternal-effect phenotype.\",\n      \"evidence\": \"Biophysical binding assays, null mice, H3K4me3 ChIP, spermatid transcriptomics, in vivo breeding\",\n      \"pmids\": [\"38719749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the paternal metabolic phenotype unresolved\", \"Sperm H3K4me3 changes only minor and non-significant\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated HP1\\u03b3-driven phase separation as the biophysical mechanism by which TRIM66 compacts facultative heterochromatin.\",\n      \"evidence\": \"In vitro LLPS reconstitution, live-cell imaging, chromatin co-localization, interaction domain mapping\",\n      \"pmids\": [\"40070663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional necessity of LLPS for in vivo gene silencing not directly tested\", \"Relationship between phase separation and Sirt6/DAX1 recruitment unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established TRIM66 as an enhancer-level repressor enforcing monogenic olfactory receptor expression, defining a physiological singular-gene-choice role.\",\n      \"evidence\": \"Conditional knockout mice, single-cell RNA-seq, enhancer binding/assembly assays, olfactory behavior tests\",\n      \"pmids\": [\"41387398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRIM66 selects which OR enhancers to repress not defined\", \"Link between enhancer assembly and the histone-reader/HP1\\u03b3 modules untested in neurons\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TRIM66's chromatin-reader and heterochromatin-forming activities mechanistically connect to its pro-oncogenic activation of cytoplasmic signaling pathways remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking nuclear repressor function to JAK2/STAT3, Wnt, and TGF-\\u03b2 activation\", \"Genome-wide direct binding map across tissues lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 10, 11]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 1, 2, 11]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CBX3\", \"NR0B1\", \"SIRT6\", \"MMP9\", \"PRDM1\", \"AR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}